Theravance Biopharma

Theravance Biopharma

Company: Theravance Biopharma, Inc. Headquarters: George Town, Grand Cayman, Cayman Islands (operational HQ: South San Francisco, CA, USA) Founded: 2014 (spin-off from Theravance, Inc.) Ticker: TBPH (NASDAQ) Employees: ~300 Market Cap: ~$1.5B (2024)

Overview

Theravance Biopharma

Company: Theravance Biopharma, Inc. Headquarters: George Town, Grand Cayman, Cayman Islands (operational HQ: South San Francisco, CA, USA) Founded: 2014 (spin-off from Theravance, Inc.) Ticker: TBPH (NASDAQ) Employees: ~300 Market Cap: ~$1.5B (2024)

Overview

Theravance Biopharma is a biopharmaceutical company with a strategic focus on gastrointestinal (GI) disorders, showcasing the intersection of enteric nervous system science and Parkinson's disease autonomic dysfunction. The company's marquee product, [Resolor (prucalopride) for chronic constipation in women](/therapeutics/prucalopride), addresses one of the most prevalent and disabling non-motor symptoms of PD — constipation affecting 60-80% of patients["@pd-gi-fasano"].

Theravance Biopharma was established as a separate entity in March 2014 when its parent company Theravance, Inc. restructured into two companies: Innoviva (retaining the respiratory franchise with GSK royalties) and Theravance Biopharma (retaining the GI program and other pipeline candidates)[@theravance-corp].

Technology Platform

5-HT4 Receptor Agonism

Mechanism of Action:

Prucalopride is a selective, high-affinity serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist:

Pharmacological Differentiation from First-Generation Prokinetics:

| Feature | Prucalopride | Metoclopramide | Domperidone |
|---------|-------------|----------------|-------------|
| Selectivity | 5-HT4 selective | D2 + 5-HT4 | D2 only |
| CNS effects | Minimal (BBB penetration low) | Moderate (psychiatric side effects) | Moderate (prolactin elevation) |
| Cardiac risk | Low | Moderate (QT prolongation) | Moderate (QT prolongation) |
| PD interaction | Safe (no dopamine antagonism) | Contraindicated (blocks dopamine) | Caution needed |

Prucalopride's 5-HT4 selectivity and PD safety profile make it uniquely positioned for the PD constipation market.

Relevance to Parkinson's Disease

Prucalopride addresses PD-associated constipation through mechanisms ideally suited for PD patients:

PD patients on levodopa commonly experience constipation-related "delayed-on" or "no-on" motor fluctuations because slowed gastric emptying delays levodopa absorption. Prucalopride can address this by accelerating GI motility and stabilizing the absorption window[@pd-gi-fasano].

Product Portfolio

Resolor (Prucalopride)

| Attribute | Details |
|-----------|---------|
| Brand Name | Resolor (EU/Canada) / Motegrity (US) |
| Generic Name | Prucalopride |
| Formulation | Oral tablets (1 mg, 2 mg) |
| Indication | Chronic constipation (women in EU; all adults in US) |
| Dosing | 2 mg once daily |
| Approvals | EU (2009), Canada (2011), US FDA (2018) |
| Manufacturer | Shire (EU/CA) to Takeda; Motegrity US by Salix/Takeda |

Efficacy in Chronic Constipation:

• Primary endpoint: ≥3 spontaneous bowel movements (SBM) per week with ≥1 per week improvement from baseline
• Response rate: ~30-40% of patients achieve primary endpoint (vs. ~20% placebo)
• Onset: Within 1-2 weeks of treatment

• Common: Headache, nausea, diarrhea, abdominal pain
• Cardiovascular: No significant QT prolongation (unlike first-generation prokinetics)
• CNS: No significant central effects (unlike metoclopramide)

Observational studies in PD patients with constipation have shown:

• Significant improvement in colonic transit time
• Reduced laxative use
• Improved stool frequency and consistency
• Potential improvement in levodopa absorption kinetics

Other Pipeline Programs

| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| Amprepotimod (TD-1473) | Inflammatory bowel disease | JAK/Tyk2 inhibitor (local GI) | Phase 2 |
| Izencitinib (TD-5202) | Crohn's disease | JAK1 selective (gut-selective) | Phase 1 |

Related Pages

Disease and Mechanism Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
• [Gut-Brain Axis in Alpha-Synuclein Propagation](/mechanisms/gut-first-brain-first-alpha-synuclein-propagation)
• [Enteric Nervous System](/entities/enteric-nervous-system)

Treatment Pages

• [Prucalopride (Resolor/Motegrity) Therapeutic Profile](/therapeutics/prucalopride)
• [PD Gastrointestinal Dysfunction Treatments](/therapeutics/pd-gastrointestinal-dysfunction)
• [Parkinson's Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)

Company Pages

• [Takeda Pharmaceuticals](/companies/takeda) (Resolor commercialization partner)
• [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)

References